[go: up one dir, main page]

SE443087B - COMPOSITION OF INHALATION COMPOSITION OF DISINODIUM CHROMOGLYCT AND LECITIN OR A SORBITAN OR SORBITOL ESTER IN A MIXTURE OF DICHLORDIFLUORMETHANE AND 1,2-DICHLOR-1,1,2,2-TETRAFLUORETHANE - Google Patents

COMPOSITION OF INHALATION COMPOSITION OF DISINODIUM CHROMOGLYCT AND LECITIN OR A SORBITAN OR SORBITOL ESTER IN A MIXTURE OF DICHLORDIFLUORMETHANE AND 1,2-DICHLOR-1,1,2,2-TETRAFLUORETHANE

Info

Publication number
SE443087B
SE443087B SE7807934A SE7807934A SE443087B SE 443087 B SE443087 B SE 443087B SE 7807934 A SE7807934 A SE 7807934A SE 7807934 A SE7807934 A SE 7807934A SE 443087 B SE443087 B SE 443087B
Authority
SE
Sweden
Prior art keywords
weight
sorbitan
composition
composition according
ester
Prior art date
Application number
SE7807934A
Other languages
Swedish (sv)
Other versions
SE7807934L (en
Inventor
K Brown
Original Assignee
Fisons Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10303374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE443087(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fisons Ltd filed Critical Fisons Ltd
Publication of SE7807934L publication Critical patent/SE7807934L/en
Publication of SE443087B publication Critical patent/SE443087B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/124Aerosols; Foams characterised by the propellant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

7807954-0 2 Vid framställning av suspensionen stelnar det ytaktiva ämnet, men det dispergeras lätt såsom små inbördes åtskilda partiklar i blandningen av drivmedel 12 och drivmedel 114. De resulterande dispersionerna är vanligen stabila under minst 30 minuter. In preparing the suspension, the surfactant solidifies, but it is easily dispersed as small spaced particles in the mixture of propellant 12 and propellant 114. The resulting dispersions are usually stable for at least 30 minutes.

Dispersionen av det ytaktiva ämnet i blandningen av drivmed- len 12 och 114 kan blandas med det finfördelade dinatriumkromoglyka- tet, som bör torkas före användningen. Dispersionens halt av det finfördelade dinatriumkromoglykatet är företrädesvis 0 ,1-10 ,0 vikt- procent och allra helst 1-5 viktprocent. Ytterligare drivmedel 12 och/eller drivmedel 114 (kylt på lämpligt sätt, t.ex. till -50°C) kan sättas till den ursprungliga dispersionen eller den ursprungliga dispersionen innehållande det finfördelade dinatriumkromoglykatet.The dispersion of the surfactant in the mixture of the fuels 12 and 114 can be mixed with the finely divided disodium chromoglycate, which should be dried before use. The dispersion content of the atomized disodium cromoglycate is preferably 0, 1-10, 0% by weight and most preferably 1-5% by weight. Additional propellant 12 and / or propellant 114 (suitably cooled, eg to -50 ° C) may be added to the original dispersion or the original dispersion containing the atomized disodium cromoglycate.

Viktförhållandet mellan drivmedel 12 och drivmedel 114 i den slutliga blandningen är såsom nämnts mellan 2:1 och 1:1, före- trädesvis ca 1,5:1. Ett överskott av drivmedel 12 i förhållande till drivmedel 114 föredrages sålunda.The weight ratio of propellant 12 to propellant 114 in the final mixture is, as mentioned, between 2: 1 and 1: 1, preferably about 1.5: 1. Thus, an excess of propellant 12 relative to propellant 114 is preferred.

Dispersionen eller suspensionen av det ytaktiva ämnet i den slutliga blandningen av drivmedlen 12 och 114 innehåller lämpligen 0,15-2,0 viktprocent lecitin eller sorbitan- eller sorbitolester, företrädesvis 0,2-1,2 viktprocent. Dessutom innehåller dylika disper- sioner eller suspensioner lämpligen 0,05-2,0 viktprocent dinatrium- kromoglykat, företrädesvis 0,2-2,0 viktprocent.The dispersion or suspension of the surfactant in the final mixture of propellants 12 and 114 suitably contains 0.15-2.0% by weight of lecithin or sorbitan or sorbitol ester, preferably 0.2-1.2% by weight. In addition, such dispersions or suspensions suitably contain 0.05-2.0% by weight of disodium chromoglycate, preferably 0.2-2.0% by weight.

Dispersioner av 0,2-2 viktdelar sorbitanester i en blandning av 50-70 viktdelar drivmedel 12 och 50-30 viktdelar 114 är stabila under minst 16 timmar vid en temperatur av -60oC.Dispersions of 0.2-2 parts by weight of sorbitan ester in a mixture of 50-70 parts by weight of propellant 12 and 50-30 parts by weight of 114 are stable for at least 16 hours at a temperature of -60 ° C.

Man föredrager särskilt sådana dispersioner, i vilka det yt- aktiva ämnet är en sorbitanester, t.ex. sorbitantrioleat ("Span 8Û"b.Particularly preferred are such dispersions in which the surfactant is a sorbitan ester, e.g. sorbitan trioleate ("Span 8Û" b.

När lecitin användes, är detta företrädesvis vegetabiliskt, t.ex. sojalecitin.When lecithin is used, it is preferably vegetable, e.g. sojalecitin.

Kompositionerna enligt uppfinningen bör innehålla mindre än 1,0 viktprocent vatten, företrädesvis mindre än 0,5 viktprocent vat- ten och allra helst mindre än 0,2 viktprocent vatten.The compositions of the invention should contain less than 1.0% by weight of water, preferably less than 0.5% by weight of water and most preferably less than 0.2% by weight of water.

Vissa kompositioner enligt uppfinningen är fördelaktiga jäm- fört med motsvarande kompositioner innehållande drivmedel 11 genom att de antingen ger en högre andel av fina partiklar i det bildade aerosolmolnet eller kan användas för framställning av dylika kompo- sitioner. En lämplig metod för bestämning av andelen fina partiklar i ett aerosolmoln beskrives i J. Phar. Pharmac. 1973, 25, Suppl. 32?-36P. 7807934-0 3 Man har överraskande funnit, att i inhalationskompositioner innehållande dinatriumkromoglykat ett viktförhållande 12:114 från 2:1 till 1:1 ger bättre resultat än ett viktförhållande lägre än 1:1. För att visa detta har man jämfört tvâ dinatriumkromoglykat- kompositioner, vilka skiljer sig åt endast vad avser förhållandet 12:114. Man har sålunda jämfört två kompositioner A och B, där komposition A är en komposition enligt uppfinningen med ett vikt- förhållande drivmedel 12:drivmedel 114 av 3:2, medan komposition B är en komposition som icke omfattas av uppfinningen (viktförhållan- det 12:114 är 2:3, dvs. det föredragna förhållandet enligt GB 988 513).Certain compositions according to the invention are advantageous over corresponding compositions containing propellant 11 in that they either give a higher proportion of fine particles in the aerosol cloud formed or can be used for the preparation of such compositions. A suitable method for determining the proportion of fine particles in an aerosol cloud is described in J. Phar. Pharmac. 1973, 25, Suppl. 32? -36P. It has surprisingly been found that in inhalation compositions containing disodium cromoglycate a weight ratio of 12: 114 from 2: 1 to 1: 1 gives better results than a weight ratio lower than 1: 1. To show this, two disodium cromoglycate compositions have been compared, which differ only in the ratio 12: 114. Thus, two compositions A and B have been compared, where composition A is a composition according to the invention with a weight ratio propellant 12: propellant 114 of 3: 2, while composition B is a composition not covered by the invention (weight ratio 12: 114 is 2: 3, i.e. the preferred ratio according to GB 988 513).

De viktigaste skillnaderna mellan de båda kompositionerna är följande: (1) Komposition B tenderar att bilda aggregat, och suspensio- nen har dålig fysikalisk stabilitet. (2) Ett dispergeringstest visar att komposition A ger unge- fär dubbelt så hög andel fina partiklar i det bildade aerosolmol- net som komposition B. En hög andel fina partiklar i aerosolmolnet är av stor betydelse när det gäller en inhalationskompositions förmåga att tränga djupt ned i lungorna.The main differences between the two compositions are as follows: (1) Composition B tends to form aggregates, and the suspension has poor physical stability. (2) A dispersion test shows that composition A gives about twice as high a proportion of fine particles in the formed aerosol cloud as composition B. A high proportion of fine particles in the aerosol cloud is of great importance in the ability of an inhalation composition to penetrate deeply in the lungs.

De jämförande försöksresultaten visar, att komposition B har försämrats avsevärt efter enbart 3,5 månader under relativt milda betingelser vid rumstemperatur. Komposition A uppvisar däremot endast obetydligt försämrade egenskaper efter 4 års lagring vid rumstemperatur.The comparative test results show that composition B has deteriorated considerably after only 3.5 months under relatively mild conditions at room temperature. Composition A, on the other hand, shows only slightly degraded properties after 4 years of storage at room temperature.

Uppfinningen illustreras genom följande utföringsexempel.The invention is illustrated by the following working examples.

Exempel. Sprayförpackningar framställdes på följande sätt.Example. Spray packages were prepared as follows.

En sorbitanester dispergeras i upp till halva mängden drivmedel 12 vid -40OC under omrörning med en blandare som ger en hög disper- sionsgrad. Torkat finmalt dinatriumkromoglykat sättes till den resulterande dispersionen, varvid detta ämne är mycket lätt att dispergera. Resten av drivmedel 12 tillsättes därefter vid -SOOC, varefter drivmedel 114 tillsättes, också kylt till -SOOC. Den resulterande blandningen fylles på tryckbehâllare, på vilka ven- tiler, t.ex. mätventiler, därefter anbringas.A sorbitan ester is dispersed in up to half the amount of propellant 12 at -40 ° C with stirring with a mixer which gives a high degree of dispersion. Dried finely ground disodium cromoglycate is added to the resulting dispersion, this substance being very easy to disperse. The remainder of propellant 12 is then added at -SOOC, after which propellant 114 is added, also cooled to -SOOC. The resulting mixture is filled into pressure vessels, on which valves, e.g. measuring valves, then fitted.

Man framställde kompositioner med följande sammansättning:Compositions having the following composition were prepared:

Claims (6)

7807934-8 4 Vikt-% Vikt-% Torkat, finmalt dinatrium- kromoglykat O,3605 1,4420 Sorbitantrioleat 0,250D 1,0000 Drivmedel 114 39,7558 39,0232 Drivmedel 12 59,6337 58,5348 Stabiliteten bestämdes på följande sätt. Tryckbehållare för- sedda med mätventiler och innehållande de ovan angivna kompositio- nerna lagrades vid 5°C, 25°C respektive 370C under en tid av 12 månader. Andra sådana spraybehållare lagrades vid (a) temperaturer som varierade från 15OC till 37oC respektive vid (b) en temperatur av 45OC under en tid av 6 månader. Under hela dessa provperioder kunde man icke iakttaga någon förändring i (a) den mängd dinatrium- kromoglykat som utmatades vid varje sprayning, (b) halten fina par- tiklar i aerosolmolnet eller (c) natriumkromoglykatets kristall- storlek. P a t e n t k r a v7807934-8 4 Weight% Weight% Dried, finely ground disodium chromoglycate 0, 3605 1.4420 Sorbitan trioleate 0.250D 1.0000 Fuel 114 39.7558 39.0232 Fuel 12 59.6337 58.5348 The stability was determined as follows. Pressure vessels equipped with measuring valves and containing the above compositions were stored at 5 ° C, 25 ° C and 37 ° C respectively for a period of 12 months. Other such spray containers were stored at (a) temperatures ranging from 15 ° C to 37 ° C and at (b) a temperature of 45 ° C for a period of 6 months. During all these test periods no change in (a) the amount of disodium chromoglycate discharged at each spraying, (b) the content of fine particles in the aerosol cloud or (c) the crystal size of the sodium cromoglycate could be observed. P a t e n t k r a v 1. Inhalationskomposition, k ä n n e t e c k n a d a v att den består av en dispersion eller suspension av 0,05-15 viktprocent dinat- riumkromoglykat med en massmediandiameter av 0,01-10 pm och lecitin eller en sorbitan- eller sorbitolester i en blandning av diklordifluormetan och 1,2-diklor-1,1,2,2-tetrafluoretan i ett viktförhållande diklordi- fluormetan: 1,2-diklor-1,1,2,2-tetrafluoretan från 2:1 till 1:1, och att den är fri från triklormonofluormetan.Inhalation composition, characterized in that it consists of a dispersion or suspension of 0.05-15% by weight of disodium cromoglycate with a mass median diameter of 0.01-10 μm and lecithin or a sorbitan or sorbitol ester in a mixture of dichlorodifluoromethane and 1 , 2-dichloro-1,1,2,2-tetrafluoroethane in a weight ratio of dichlorodifluoromethane: 1,2-dichloro-1,1,2,2-tetrafluoroethane from 2: 1 to 1: 1, and that it is free from trichloromonofluoromethane. 2. Komposition enligt krav 1, k ä n n e t e c k n a d a v att den innehåller mindre än 4,0 viktprocent lecitin eller sorbitan- eller sorbitolester.Composition according to Claim 1, characterized in that it contains less than 4.0% by weight of lecithin or sorbitan or sorbitol ester. 3. Komposition enligt krav 2, k ä n n e t e c k n a d a V att den innehåller 0,2-2,0 viktprocent lecitin eller sorbitan- eller serbi- tolester.3. A composition according to claim 2, characterized in that it contains 0.2-2.0% by weight of lecithin or sorbitan or serbitol ester. 4. Komposition enligt krav 3, k ä n n e t e c k n a d a v att den innehåller 0,1-10 víktprocent dinatriumkromoglykat.4. A composition according to claim 3, characterized in that it contains 0.1-10% by weight of disodium cromoglycate. 5. Komposition enligt något av kraven 1-4, k ä n n e t e c k n a 3 a v att estern är sorbitanseskvioleat, sorbitanmonooleat, sorbitan- monolaurat eller sorbitantrioleat.Composition according to any one of claims 1-4, characterized in that the ester is sorbitan sesvioleate, sorbitan monooleate, sorbitan monolaurate or sorbitan trioleate. 6. Komposition enligt något av kraven 1-5, k ä n nle t.e c k n a d a v *att den innehåller mindre än 1 viktnrocent vatten. Pooa QUALITYComposition according to any one of claims 1-5, characterized in that it contains less than 1% by weight of water. Pooa QUALITY
SE7807934A 1977-07-19 1978-07-18 COMPOSITION OF INHALATION COMPOSITION OF DISINODIUM CHROMOGLYCT AND LECITIN OR A SORBITAN OR SORBITOL ESTER IN A MIXTURE OF DICHLORDIFLUORMETHANE AND 1,2-DICHLOR-1,1,2,2-TETRAFLUORETHANE SE443087B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB3016977 1977-07-19

Publications (2)

Publication Number Publication Date
SE7807934L SE7807934L (en) 1979-01-20
SE443087B true SE443087B (en) 1986-02-17

Family

ID=10303374

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7807934A SE443087B (en) 1977-07-19 1978-07-18 COMPOSITION OF INHALATION COMPOSITION OF DISINODIUM CHROMOGLYCT AND LECITIN OR A SORBITAN OR SORBITOL ESTER IN A MIXTURE OF DICHLORDIFLUORMETHANE AND 1,2-DICHLOR-1,1,2,2-TETRAFLUORETHANE

Country Status (15)

Country Link
JP (1) JPS5435209A (en)
AU (1) AU522792B2 (en)
BE (1) BE869055A (en)
CA (1) CA1112567A (en)
CH (1) CH627075A5 (en)
DE (1) DE2831419A1 (en)
FR (1) FR2397833A1 (en)
HK (1) HK51585A (en)
IE (1) IE47128B1 (en)
IL (1) IL55161A (en)
IT (1) IT1158890B (en)
MY (1) MY8400252A (en)
NL (1) NL7807625A (en)
NZ (1) NZ187894A (en)
SE (1) SE443087B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
HU205249B (en) * 1990-11-09 1992-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing suspensive aerosole composition
DE4425255A1 (en) 1994-07-16 1996-01-18 Asta Medica Ag Formulation for inhalation application

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB367276A (en) * 1931-06-20 1932-02-18 Schmidt Sche Heissdampf Improvements in or relating to independently fired steam superheaters
BE555319A (en) * 1956-03-21 1900-01-01
BE556587A (en) * 1957-01-31 1957-04-11
GB1144905A (en) * 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
US3513104A (en) * 1965-03-26 1970-05-19 Colgate Palmolive Co Self-propelling powder compositions
US3560507A (en) * 1968-02-27 1971-02-02 Millmaster Onyx Corp Quaternary ammonium alkenyl succinates
GB1384895A (en) * 1971-01-25 1975-02-26 Colgate Palmolive Co Fabric conditioning
DE2151706B1 (en) * 1971-10-18 1973-05-03 Cegla, Ulrich, Dr med , 600 0 Frank fürt Niederrad Tantalum-contg x-ray contrast agents - in aerosol form for bronchography
IL44022A0 (en) * 1973-01-23 1974-05-16 Fisons Ltd Novel salts of anti-inflammatory quinoline derivatives,their preparation and pharmaceutical compositions containing them
IT1039699B (en) * 1975-07-03 1979-12-10 Prephar SPERMICIDE COMPOSITION BASED ON BENZISOTHIAZOLIC DERIVATIVES
GB1562901A (en) * 1976-01-30 1980-03-19 Fisons Ltd Disodium cromoglycate
FI770215A (en) * 1976-01-30 1977-07-31 Fisons Ltd
GB2001334B (en) 1977-07-19 1982-03-03 Fisons Ltd Pressurised aerosol formulation
GB1590126A (en) 1977-11-23 1981-05-28 Booth B H Method of bulking yarns

Also Published As

Publication number Publication date
IT1158890B (en) 1987-02-25
DE2831419C2 (en) 1989-01-05
MY8400252A (en) 1984-12-31
FR2397833B1 (en) 1982-06-25
HK51585A (en) 1985-07-12
JPS6411615B2 (en) 1989-02-27
AU3805778A (en) 1980-01-17
IL55161A (en) 1981-12-31
CA1112567A (en) 1981-11-17
AU522792B2 (en) 1982-06-24
CH627075A5 (en) 1981-12-31
NZ187894A (en) 1984-05-31
IE47128B1 (en) 1983-12-28
IT7825845A0 (en) 1978-07-18
BE869055A (en) 1979-01-17
SE7807934L (en) 1979-01-20
FR2397833A1 (en) 1979-02-16
IE781432L (en) 1979-01-19
NL7807625A (en) 1979-01-23
JPS5435209A (en) 1979-03-15
IL55161A0 (en) 1978-09-29
DE2831419A1 (en) 1979-02-01

Similar Documents

Publication Publication Date Title
US3738852A (en) Cationic bituminous emulsion
SE442267B (en) PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION CONTAINING THE DINATRIUM SALT OF 1,3-BIS (2-CARBOXICROMON-5-YLOXI) PROPAN-2-OL
SE414704B (en) PROCEDURE FOR THE MANUFACTURING OF PRICK-FORCING GRAIN WITH MAIN UNIQUE FORM AND SIZE FOR DENTALS
SE438275B (en) MIX-FREE IRON-BASED POWDER MIX
CA1097072A (en) Halogenated organic compound with metal fuel and silver iodate as pyrotechnic cloud seeding composition
SE443087B (en) COMPOSITION OF INHALATION COMPOSITION OF DISINODIUM CHROMOGLYCT AND LECITIN OR A SORBITAN OR SORBITOL ESTER IN A MIXTURE OF DICHLORDIFLUORMETHANE AND 1,2-DICHLOR-1,1,2,2-TETRAFLUORETHANE
US3085889A (en) Emulsions stabilized against freezing
DE2348926A1 (en) FIXED FIRE EXTINGUISHING COMPOSITIONS
EP0067560B1 (en) Gelatinized highly explosive composition and method of preparation
DE1719443C3 (en)
US2356776A (en) Composition for preparation of oil base drilling fluid
US2506635A (en) Ddt insecticide dust and process for making same
US2733139A (en) Cast explosive composition
JPH03157327A (en) Powdery aerosol composition
US3166555A (en) Ammonium nitrate-hexamethylene-tetramine adduct
US2922703A (en) Incendiary fuels
US2159999A (en) Preventing the caking of sodium perborate
Francis Jr A note on the use of magnesium oxide in combustion tube fillings
US2820761A (en) Carbon dioxide composition
US3197321A (en) Spray composition
US2168563A (en) Nitrostarch explosive
GB669709A (en) Procaine-penicillin g composition
GB841304A (en) Improvements in or relating to additive materials for rendering cement water resistant
DE2835494A1 (en) Prodn. of porous rubber articles - using eutectic mixtures of urea-acetamide-emulsifier which are homogeneously distributed
SU802326A1 (en) Polimeric composition

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7807934-0

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7807934-0

Format of ref document f/p: F